CN108714220A - Cysteine engineered Antibody-toxin conjugate - Google Patents

Cysteine engineered Antibody-toxin conjugate Download PDF

Info

Publication number
CN108714220A
CN108714220A CN201810371080.XA CN201810371080A CN108714220A CN 108714220 A CN108714220 A CN 108714220A CN 201810371080 A CN201810371080 A CN 201810371080A CN 108714220 A CN108714220 A CN 108714220A
Authority
CN
China
Prior art keywords
antibody
ser
pab
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810371080.XA
Other languages
Chinese (zh)
Other versions
CN108714220B (en
Inventor
朱义
王茜
王一茜
卓识
李�杰
陈澜
余永国
万威李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu bailidote Biological Pharmaceutical Co.,Ltd.
Original Assignee
Sichuan Baili Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Baili Pharmaceutical Co Ltd filed Critical Sichuan Baili Pharmaceutical Co Ltd
Priority to CN201810371080.XA priority Critical patent/CN108714220B/en
Publication of CN108714220A publication Critical patent/CN108714220A/en
Application granted granted Critical
Publication of CN108714220B publication Critical patent/CN108714220B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

It transform 205 valines (V) of 235 serines (S) of heavy chain and light chain of target antibody as cysteine (C), and site-directed coupling is carried out with the mc-vc-PAB-OH connexons for being coupled small molecule high activity cytotoxin (Payload) by the free sulfhydryl groups (- SH) of this improved cysteine, form the excellent cysteine engineered Antibody-toxin conjugate of homogeneity, its toxin is 3.2-4.0 than antibody ratios (DAR), this Antibody-toxin conjugate has general formula：1C7-HC-S235C-LC-V205C-mc-vc-PAB-payload, meanwhile, invention further discloses the preparation of this TDC drug, purification process, in the treatment use for the tumour for being overexpressed EGFRwt.

Description

Cysteine engineered Antibody-toxin conjugate
Technical field
The present invention relates to a kind of compounds and its preparation method and application, more particularly to a kind of cysteine engineered resists Toxin conjugated object of body-(TDC) and its preparation method and application.
Background technology
EGF-R ELISA EGFR (Epidermal Growth Factor Receptor) is a kind of glycoprotein, is belonged to In one kind of ErbB receptor family, which includes EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) With Her 4 (ErbB-4).EGFR is the receptor of epidermal growth factor (EGF) cell Proliferation and signal transduction, penetrates through cell membrane, point Son amount 170KDa, by being activated with ligand binding.After activation, EGFR is converted into dimer by monomer.EGFR is also possible to and ErbB Other members of receptor family polymerize to activate, such as ErbB2/Her2/neu.
The usual low amounts of EGFR is expressed in a variety of normal tissue cells, including skin, liver etc., and phase is acted on normal physiological It closes.
EGFR be overexpressed it is related with development to the generation of kinds of tumors, including head and neck cancer, carcinoma of urinary bladder, oophoroma, it is non-it is small carefully Born of the same parents' lung cancer, colorectal cancer, glioma, kidney, prostate cancer, cancer of pancreas, breast cancer (Atalay et al., 2003； Herbst and Shin,2002)。
Antibody-toxin conjugate (Antibody drug conjugate, ADC) is the hot fields of targeted therapy, is existed Two drugs Adcetris and Kadcyla of the granted listing in the U.S. show good clinical efficacy, and have more than 50 ADC Drug is carrying out clinical stage research.
Invention content
The cysteine engineered Antibody-toxin conjugate (TDC) of the compound of the present invention has general formula： 1C7-HC- S235C-LC-V205C-mc-vc-PAB-payload.Wherein 1C7 is 235 serines (S) of parental antibody 1A5 heavy chains and light 205 valines (V) of chain transform the antibody after cysteine (C) as.The heavy chain amino acid sequence of 1C7 is SEQ ID NO:12, The light-chain amino acid sequence of 1C7 is SEQ ID NO:14.The parental antibody 1A5 heavy chain amino acid sequences of 1C7 are SEQ ID NO: 16,1A5 light-chain amino acid sequence is SEQ ID NO:18.1C7 maintains the ability of its parental antibody 1A5 and antigen binding (affinity), antigen are the wild-type egf receptor (EGFRwt) of people.1C7 passes through its heavy chain 235 and light chain The cysteine sulfydryl of 205 transformations carries out Antibody-toxin conjugate (TDC) site-directed coupling, poison with mc-vc-PAB-payload Element is 3.2-4.0 than antibody ratios DAR.Cysteine engineered Antibody-toxin conjugate (TDC) drug of the compound of the present invention It is mainly used for the tumour that treatment is overexpressed EGFRwt, including head and neck cancer, colorectal cancer, brain colloid carcinoma, cancer of pancreas, non-small cell lung Cancer, carcinoma of urinary bladder, colorectal cancer, kidney, prostate cancer, breast cancer etc..
Description of the drawings
Fig. 1 is 25 experimental result picture of embodiment；
Fig. 2,3,12-14 are 28 experimental result picture of embodiment；
Fig. 4,5 are 29 experimental result picture of embodiment；
Fig. 6 is 30 experimental result picture of embodiment；
Fig. 7-9 is 26 experimental result picture of embodiment；
Figure 10,11 are 27 experimental result picture of embodiment.
Specific implementation mode
All features disclosed in this specification or disclosed all methods or in the process the step of, in addition to mutually exclusive Feature and/or step other than, can combine in any way.
The synthesis of 1 mc of embodiment
The maleic anhydride 3.5g of 6-aminocaprolc acid 3.9g (0.03mol) and 1.2eq are added in 30ml glacial acetic acid (0.036mol).Reaction solution is stirred to react 4~6h in 120 DEG C.After completion of the reaction, stop heating, naturally cool to room temperature.60℃ It is concentrated under reduced pressure and removes most of acetic acid.Gained brown color viscous fluid is poured into water, and is added the extractions of ethyl acetate 20ml × 3, is closed And organic layer.Organic layer uses water, saturated common salt water washing, anhydrous sodium sulfate drying to filter successively, and filtrate decompression is concentrated to give palm fibre Yellow oil is added the stirring of 50ml water, there is off-white powder precipitation, filters, 50 DEG C of target product 5.08g being dried under reduced pressure, Yield 80%.mp： 89-92℃.m/z：212.2[M+H]+.1HNMR(400Mz,DMSO)：13.21(br,1H,COOH), 6.75 (s, 2H, COCH=CHCO), 3.63 (t, 2H, J=7.2Hz, NCH2CH2), 2.42 (t, 2H, J=7.4Hz, CH2COOH)、1.52-1.68(m,4H,NCH2CH2CH2CH2)、1.30-1.42 (m,2H,NCH2CH2CH2CH2)。
The synthesis of 2 Mc-OSu of embodiment
4.7g (22mmol) MC and 25g (22mmol) HOSu is added in 50ml acetonitriles under nitrogen protection.Separately take 4.5g (22mmol) DCC is dissolved in 25ml acetonitriles, is kept interior temperature at 0 DEG C or so, is slowly dropped into reaction solution.Reaction solution is in 0 DEG C Reaction reacts at room temperature overnight again after 2 hours.Filtering, filter cake are washed with acetonitrile 10ml × 3, and filtrate decompression is concentrated to dryness.Gained oil Shape object obtains light tan solid 6.4g, yield 95% in reduced pressure at room temperature 6h.(do not purify and directly cast single step reaction) m/z： 309.2[M+H]+.1HNMR (400Mz,CDCl3)：1~2 (m, 6H, CCH2CH2CH2C), 2.68 (t, 2H, CH2CO), 2.95 (s, 4H, COCH2CH2CO), 3.68 (t, 2H, CH2N), 6.81 (s, 2H, CH=CH).
The synthesis of 3 Fmoc-Val-OSu of embodiment
Fmoc-Val 10g and HOSu 3.4g are added in 100mlTHF.Separately DCC6g is taken to be dissolved in 50ml acetonitriles, kept Interior temperature is slowly dropped at 0 DEG C or so in reaction solution.Reaction 24 hours is stirred at room temperature in reaction solution.Filtering, filter cake THF Washing, filtrate decompression are concentrated to give transparent oil.Grease is not purified directly to cast single step reaction.m/z：437.4[M+H] +。
The synthesis of 4 Fmoc-vc of embodiment
In 20mlTHF be added Cit 4.0g (1.05eq) and sodium bicarbonate aqueous solution 60ml (NaHCO3 2g, 1.05eq).Separately 22.35mmolFmoc-Val-OSu is taken to be dissolved in 60mlDME, then is added into reaction solution.Reaction solution is in room It is stirred to react under temperature 24 hours.After completion of the reaction, 15% aqueous citric acid solution 110ml is added into system, is then extracted again with EA It takes twice, merges organic layer, be concentrated under reduced pressure to give white solid.And methyl tertiary butyl ether(MTBE) 100ml is added into white solid and stirs It washes, filters, filter cake is dried under reduced pressure 4h in 40 DEG C and obtains product 4.83g, yield 65%.m/z：497.6(M+H)+.1HNMR (400Mz,DMSO):0.92 (6H, m), 1.35~1.65 (4H, m), 2.10 (1H, m), 3.01 (2H, q), 3.99 (1H, t), 4.01-4.45(2H, m)、4.45(2H,t)、5.46(2H,br)、6.03(1H,t)、7.20-8.02(8H,m)、8.25(1H, d)。
The synthesis of 5 Fmoc-vc-PABOH of embodiment
In reaction bulb be added DCM/MeOH=2/1 mixed solvent 60ml, add Fmoc-vc 2g (4.2mmol) and PABOH 1.04g (2eq) add EEDQ 2.0g (2eq) behind stirring and dissolving part.Reaction system is protected from light at ambient temperature It is stirred to react 2.0d.After completion of the reaction, it is concentrated under reduced pressure to give white solid for 40 DEG C.White solid is collected, methyl tertbutyl is added Ether 100ml, which is stirred, to be washed, and filtering, filter cake is washed with methyl tertiary butyl ether(MTBE), and 40 DEG C of gained white solid is dried under reduced pressure to obtain 2.2g, yield About 88%.m/z：602.6(M+H)+. 1HNMR(400Mz,DMSO):0.95 (6H, m), 1.45~1.69 (4H, m), 2.10 (1H, m), 3.11 (2H, m), 3.99 (1H, m), 4.30 (2H, d), 4.05~-4.66 (2H, m), 4.55 (2H, d), 5.21 (1H,t)、 5.51(2H,br)、6.11(1H,t)、7.09-8.10(12H,m)、8.21(1H,d)、10.51(1H,br)。
The synthesis of 6 vc-PABOH of embodiment
Fmoc-vc-PABOH 490mg (0.815mmol) stirring and dissolving is added in 10mlNMP, adds diethylamine 2ml.It is stirred to react at room temperature for 24 hours.After completion of the reaction, 20mlDCM stirrings are added in 40 DEG C of reduced pressures, gained grease Crystallization, filtering, filter cake are washed with DCM, and obtained solid is dried under reduced pressure to obtain 277mg, yield 90%.m/z：380.2(M+H)+. 1HNMR(400Mz,DMSO):0.89 (6H, m), 1.31~1.61 (4H, m), 1.82 (1H, m), 2.86 (1H, m), 2.89 (2H, d),4.38(2H,d),4.44 (1H,m),5.01(1H,br),5.35(2H,br),5.84(1H,br),7.14(2H,d),7.42 (2H,d),8.08 (1H,br),9.88(1H,br)。
The synthesis of 7 mc-vc-PABOH of embodiment
Vc-PABOH 205mg (0.54mmol) and MC-OSu 184mg (1.1eq) are added in 10mlNMP, finish in It is stirred to react at room temperature for 24 hours.Reaction finishes, and 20ml methyl tertiary butyl ether(MTBE)s, which are added, in 40 DEG C of reduced pressures, gained grease stirs Mix crystallization.Filtering, filter cake are washed with methyl tertiary butyl ether(MTBE), obtain 310mg products, yield 100%.m/z:573.3(M+H)+. 1HNMR(400Mz,DMSO):0.89 (6H,m)、1.15-1.99(10H,m)、2.11(1H,m)、2.31(2H,t)、3.21(2H, m)、3.53(2H, t)、4.32(1H,t)、4.51(1H,m)、4.59(2H,br)、5.24(1H,br)、5.56(2H,br)、6.20 (1H, br)、7.12(2H,s)、7.23(2H,d),7.58(2H,d)、7.94(1H,d),8.1 7(1H,d)、10.21(1H, br)。
The synthesis of 8 mc-vc-PAB-PNP of embodiment
Mc-vc-PABOH 168.6mg (0.294mmol) are taken to be dissolved in 5ml anhydrous pyridines under nitrogen protection, reactant System is cooled to 0 DEG C or so.Separately PNP179mg (3eq) is taken to be dissolved in 5mlDCM, then is slowly added into reaction system.And in Ice bath is removed after 0 DEG C or so holding 10min, reacts 3h then at being stirred at room temperature.Reaction finishes, and 70mlEA and 100ml is added 15% aqueous citric acid solution divides and takes organic layer.Organic layer uses citric acid, water, saturated common salt water washing, then anhydrous sodium sulfate successively Dry, filtering, filtrate decompression is concentrated to dryness to obtain light yellow oil, and methyl tertiary butyl ether(MTBE) crystallization is added and obtains off-white powder 86mg, yield 40%.m/z:738(M+H)+.1HNMR(400Mz,CDCl3/CD3OD):0.84(6H,m),1.11-1.84 (10H,m)、2.05(1H,m)、2.15(2H,t)、3.09(2H,m)、3.32(2H,t)、4.12(1H,m)、 4.38(1H,m)、 5.15(2H,s)、6.61(2H,s)、6.84(1H,d),7.61(1H,d)、7.21(2H,d),7.50 (2H,d)、7.61(2H, d),8.18(2H,d)、9.59(1H,br)。
The synthesis of 9 mc-vc-PAB-MMAE of embodiment
20mg mc-vc-PAB-PNP (1.5eq) and 3mgHOBT are added in 2mlDMF.It is stirred at room temperature in a moment, is added 13mgMMAE, 0.5ml pyridine, 25ulDIEA.Reaction solution is stirred to react 2d at room temperature.After completion of the reaction, reaction solution is directly used Column purification is prepared, is lyophilized after collecting required ingredient concentration, obtains about 10mg products, yield about 42%.m/z:1317.1(M+H) +。
The synthesis of 10 mc-vc-PAB-MMAF of embodiment
According to the operation of embodiment 9, mc-vc-PAB-MMAF about 12.5mg, yield 45.2%, m/z are obtained: 1331.7(M +H)+。
The synthesis of 11 mc-vc-PAB-PBD of embodiment
According to the operation of embodiment 9, mc-vc-PAB-PBD about 9.5mg, yield 32.5%, m/z are obtained: 1325.4(M+ H)+。
The synthesis of 12 mc-vc-PAB-DOX of embodiment
According to the operation of embodiment 9, mc-vc-PAB-DOX about 11.2mg, yield 38.9%, m/z are obtained: 1143.2(M+ H)+。
The synthesis of 13 mc-vc-PAB-SN-38 of embodiment
After the 10-O-Boc-SN-38 of 100mg purchases is dissolved with the dichloromethane that 10ml is dried, 25.6mg is added The dichloromethane solution (62mg triphosgenes 2ml dichloromethane dissolves) of triphosgene is added dropwise in (1eq) DMAP at 0 DEG C, and drop finishes, It continues at 0 DEG C and reacts 12h, dichloromethane is removed under reduced pressure, after the DMF dissolvings of 10ml dryings, 144mg mc-vc- are added PABOH, goes to and is stirred at room temperature for 24 hours, obtains mc-vc-PAB-SN-38 41mg by preparing liquid phase separation, two step yields are always 19.7%, m/z: 992.1(M+H)+.
The expression and purification of 14 1C7 antibody of embodiment
Use FreestyleTM293-F (Invitrogen) suspension cell expresses 1C7 antibody.The day before transfection, with 6 × 105A/mL density is by cell inoculation in the complete mediums of F17 containing 300mL (FreestyleTMF17 expresses culture medium, Gibco Company) 1L shaking flasks in, 37 DEG C, 5%CO2, 120rpm cell culture tables are incubated overnight.Next day carries out antibody expression with PEI The transfection of plasmid, wherein plasmid:PEI ratios are 2:1.TN1 supplemented mediums are added one day after, by 2.5% (v/v) in transfection, after Supernatant is collected by centrifugation after 4 days in continuous culture.
Obtained cell expression supernatant is collected, (Mabselect Sure LX, GE are public through Protein A affinity columns Department), it is eluted with 0.1M citric acids (pH3.0), the antibody of capture is adjusted to 1M Tris-HCl (pH9.0) by 1/10 (v/v) PH7.0, then the impurity such as polymer and endotoxin are removed by gel permeation chromatography column SEC (Superdex 200, GE company), Antibodies buffer is replaced as PBS (pH7.4) simultaneously, collects UV280nm target peaks sample through ultra-filtration centrifuge tube (30KD, Pall Company) it is concentrated into 5mg/ml.
The 1C7 antibody obtained by the method, a concentration of 5mg/ml, target antibody monomer (POI%) are more than 98%, use In follow-up test.
Embodiment 15 prepares 1C7-HC-S235C-LC-V205C-mc- by being coupled 1C7 antibody and mc-vc-PAB-MMAE Vc-PAB-MMAE TDC samples
The 1C7 antibody of cell expression, purifies by Mabselect Sure, and Tris solution is added at once after low pH elutions It neutralizes, and changes the Tris-HCl buffer solutions that liquid is pH7.5.Compound mc-vc-PAB-MMAE, white powder are dissolved in It is spare in DMA.In order to remove the screen on mutation cysteine residues, need first to restore antibody.According to 20 times of molecular proportions The DTT aqueous solutions of 1M are added in 1C7 antibody-solutions, are reacted 4 hours for 20 DEG C after mixing.Reaction time arrive after by the pH tune of sample It is whole to remove the DTT and screen in sample to 5.0, and by SP Sepharose F.F. cation-exchange chromatographies.Then according to DHAA solution is added in sample 10 times of molecular proportions, and 25 DEG C are protected from light 3 hours, and antibody interchain disulfide bond is made to reconnect.So Mc-vc-PAB-MMAE solution is added afterwards so that mc-vc-PAB-MMAE is coupled with antibody mutation cysteine, fully mixed It is reacted 1 hour for 25 DEG C after even.The removal of SP Sepharose F.F. cation-exchange chromatographies is used not to be coupled after reaction anti- The mc-vc-PAB-MMAE of body molecule obtains 1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAE TDC samples.
Embodiment 16 prepares 1C7-HC-S235C-LC-V205C-mc- by being coupled 1C7 antibody and mc-vc-PAB-MMAF Vc-PAB-MMAF TDC samples
According to the operating procedure of embodiment 15,1C7-HC- is prepared by being coupled 1C7 antibody and mc-vc-PAB-MMAF S235C-LC-V205C-mc-vc-PAB-MMAF TDC。
Embodiment 17 prepares 1C7-HC-S235C-LC-V205C-mc- by being coupled 1C7 antibody and mc-vc-PAB-PBD Vc-PAB-PBD TDC samples
According to the operating procedure of embodiment 15,1C7-HC- is prepared by being coupled 1C7 antibody and mc-vc-PAB-PBD S235C-LC-V205C-mc-vc-PAB-PBDTDC。
Embodiment 18 prepares 1C7-HC-S235C-LC-V205C-mc- by being coupled 1C7 antibody and mc-vc-PAB-SN38 Vc-PAB-SN38TDC samples
According to the operating procedure of embodiment 15,1C7-HC- is prepared by being coupled 1C7 antibody and mc-vc-PAB-SN38 S235C-LC-V205C-mc-vc-PAB-SN38TDC。
Embodiment 19 prepares 1C7-HC-S235C-LC-V205C-mc- by being coupled 1C7 antibody and mc-vc-PAB-Dox Vc-PAB-Dox TDC samples
According to the operating procedure of embodiment 15,1C7-HC- is prepared by being coupled 1C7 antibody and mc-vc-PAB-Dox S235C-LC-V205C-mc-vc-PAB-Dox TDC。
Embodiment 20 prepares 1A5-mc-vc-PAB-MMAE ADC samples by being coupled 1A5 antibody and mc-vc-PAB-Dox
The 1A5 antibody of cell expression, purifies by Mabselect Sure, and Tris solution is added at once after low pH elutions It neutralizes, and changes the Tris-HCl buffer solutions that liquid is pH7.5.Mc-vc-PAB-MMAE, white powder are dissolved in standby in DMA With.In order to open the interchain disulfide bond of antibody, need first to restore antibody.According to 20 times of molecular proportions by the DTT aqueous solutions of 1M It is added in 1A5 antibody-solutions, is reacted 4 hours for 20 DEG C after mixing.Reaction time adjusts the pH of sample to 5.0 after, and passes through SP Sepharose F.F. cation-exchange chromatographies remove the DTT in sample.Then mc-vc-PAB-MMAE solution is added, makes The cysteine residues for obtaining mc-vc-PAB-MMAE and antibody and the interchain disulfide bond of opening are coupled, 25 after mixing well DEG C reaction 1 hour.The removal of SP Sepharose F.F. cation-exchange chromatographies is used not to be coupled antibody molecule after reaction Mc-vc-PAB-MMAE.Obtain 1A5-mc-vc-PAB-MMAE ADC samples.
Embodiment 21 prepares 1A5-mc-vc-PAB-MMAF ADC samples by being coupled 1A5 antibody and mc-vc-PAB-MMAF Product
According to the operating procedure of embodiment 20,1A5-mc-vc- is prepared by being coupled 1A5 antibody and mc-vc-PAB-MMAF PAB–MMAF ADC。
Embodiment 22 prepares 1A5-mc-vc-PAB-PBD ADC samples by being coupled 1A5 antibody and mc-vc-PAB-PBD
According to the operating procedure of embodiment 20,1A5-mc-vc- is prepared by being coupled 1A5 antibody and mc-vc-PAB-PBD PAB-PBD ADC。
Embodiment 23 prepares 1A5-mc-vc-PAB-SN38 ADC samples by being coupled 1A5 antibody and mc-vc-PAB-SN38
According to the operating procedure of embodiment 20,1A5-mc-vc- is prepared by being coupled 1A5 antibody and mc-vc-PAB-SN38 PAB-SN38ADC。
Embodiment 24 prepares 1A5-mc-vc-PAB-Dox ADC samples by being coupled 1A5 antibody and mc-vc-PAB-Dox
According to the operating procedure of embodiment 20,1A5-mc-vc- is prepared by being coupled 1A5 antibody and mc-vc-PAB-Dox PAB-Dox ADC。
25 RP-HPLC of embodiment detects toxin than antibody ratios DAR
TDC and ADC samples are analyzed with the reversed chromatography method of high performance liquid chromatography, according to corresponding calculated by peak area DAR.Specifically Method is as follows：
Chromatographic column：Proteomix RP-1000 (4.6*100mm, 5 μm)；
Mobile phase A：0.1% TFA aqueous solutions；B：0.1% TFA acetonitrile solutions
1M DTT storing liquids in the TDC and ADC of 1mg/ml, make the final concentration of 100mM of DTT, in 37 DEG C after each sample mixing Heating water bath 60min.
70% mobile phase A is balanced with 30% Mobile phase B, mobile phase A and B gradient elutions, 80 DEG C, 214nm detections.DAR is counted Calculating formula is：DAR=[LC-1D areas/(LC area+LC-1D areas)+HC-1D areas/(HC area+HC-1D areas)] × 2.
According to site-directed coupling DAR=3.4 is calculated, compound homogeneity is fine.
Subordinate list 1,1C7-HC-S235C-LC-V205C-mc-vc-PAB-payload TDC, 1A5-mc-vc-PAB- Payload ADC coupling efficiency DAR tables
Subordinate list 1 is shown, higher (theoretical by the cysteine engineered TDC compound coupling efficiencies for carrying out site-directed coupling Peak is 4.0) DAR >=3.4, and product homogeneity is considerably better than non-by antibody native interchain disulfide bond progress cysteine The ADC compounds of site-directed coupling (DAR theoretical upper values are 8.0).
Embodiment 26 SEC-HPLC detections TDC assembles situation
By TDC Sample storages in 37 DEG C, it is analyzed with SEC-HPLC respectively within the 0th, 14 day and assemble situation, specific method is such as Under：
Chromatographic column：TSKgel SuperSW mAb HR(7.8mm×30cm)
Mobile phase：The phosphate buffer of 0.15M, pH7.0.
25 DEG C, 214nm detections.
SEC-HPLC detects 1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAE TDC and assembles situation, and sample is in 37 DEG C storage 2 weeks, aggregation content does not change substantially.
SEC-HPLC detections carry out the 1A5-mc-vc- of the non-site-directed coupling of cysteine by antibody native interchain disulfide bond PAB-MMAE ADC samples, sample detect immediately after being coupled, and there are about 48% aggregations, including a large amount of high molecular weight Aggregation.
Subordinate list 2,1C7-HC-S235C-LC-V205C-mc-vc-PAB-payload TDC, 1A5-mc-vc-PAB- Payload ADC subject monomers content lists
Subordinate list 2 is shown, the ADC compound targets of the non-site-directed coupling of cysteine are carried out by antibody native interchain disulfide bond Content of monomer is substantially less than through the cysteine engineered TDC compounds for carrying out site-directed coupling.
27 TDC of embodiment maintains affinity of the skeleton antibody 1C7 and original antibodies 1A5 for EGFRvIII
The relative affinity of TDC, 1C7 and 1A5 for EGFRwt is compared with indirect elisa method.It is as follows：
Recombinate EGFRwt-His*6 antigen wrapper sheets；Fishskin gelatin is closed；1A5,1C7,1C7-HC-S235C- are diluted respectively LC-V205C-mc-vc-PAB-MMAE TDC、 1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAF TDC、 1C7- HC-S235C-LC-V205C-mc-vc-PAB-PBD TDC、 1C7-HC-S235C-LC-V205C-mc-vc-PAB-SN38TDC、 1C7-HC-S235C-LC-V205C-mc-vc-PAB-DOX TDC, maximum concentration 50ug/ml, 4 times of gradient dilutions, totally 11 it is dense Degree；The secondary antibody of HRP labels is incubated；TMB develops the color, and detects and is absorbed at 450nm.Testing result maps to concentration with A450,1C7, idol TDC after connection maintains affinity similar with 1A5, EC50 values very close to；Illustrate heavy chain S235C and light chain V205C on 1A5 Rite-directed mutagenesis and the site-directed coupling of 1C7 and mc-vc-PAB-payload do not influence the affinity of itself and EGFRwt antigens.
1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAE TDC and 1C7 maintains 1A5 and antigen EGFRwt's Affinity.
1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAE TDC、 1C7-HC-S235C-LC-V205C-mc- vc-PAB-MMAF TDC、 1C7-HC-S235C-LC-V205C-mc-vc-PAB-PBD TDC、 1C7-HC-S235C-LC- V205C-mc-vc-PAB-SN38TDC, 1C7-HC-S235C-LC-V205C-mc-vc-PAB-DOX TDC maintain 1A5 and resist The affinity of former EGFRwt, 1C7-HC-S235C-LC-V205C-mc-vc-PAB-payload can be with a variety of small molecular cells poison Element carries out site-directed coupling and keeps Ag-Ab affinity.
28 cytotoxicity Composition analyzed of embodiment
The cellular cytoxicity activity of TDC and ADC is measured by following experiments process：TDC and ADC are added separately to EGFR mistakes In the tumor cell culture base for measuring the people of expression, cell culture measures cell survival rate after 72 hours.External reality based on cell Test the apoptosis for measuring cell survival rate, cytotoxicity and TDC of the present invention inductions.
The pharmacy in vitro of Antibody-toxin conjugate is measured by cell proliferation test. AqueousOne Solution Cell Proliferation Assay are commercially available (Promega Corp., Madison, WI). CellTiterAQueous One Solution Cell Proliferation Assay (a) be it is a kind of with colorimetric method come Detect the detection reagent of cell Proliferation and the living cells quantity in cytotoxicity experiment.This reagent is containing there are one novel tetrazoliums Close object [3- (4,5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- (4- sulfophenyl)-2H-tetrazolium,inner salt；MTS] and a kind of electron coupling agent (phenazine ethosulfate；PES).PES has the chemical stability of enhancing, this makes it that can be mixed to form stable solution with MTS.It is this Easily " single solution " pattern is in first generation CellTiterImprovement on the basis of AQueous Assay, CellTiterWhat the electron coupling agent PMS used in AQueous Assay was provided separately from MTS solution.MTS (Owen ' s reagent) becomes a kind of coloured formazan product by cell biological reduction, can be directly dissolved in culture medium (figure 1).It is completed under the action of this NADPH or NADH for converting the dehydrogenase generation being likely in the active cell of metabolism. It, only need to be by a small amount of CellTiter when detectionAQueous One Solution Reagent are directly added into cultivation plate hole Culture medium in, be incubated 1-4 hour, then with microplate reader read 490nm absorbance value.
Detect that the amount of formazan products is directly proportional to the viable count in culture at 490nm.Due to MTS formazans Product is solvable in tissue culture medium (TCM), CellTiterAQueous One Solution Assay and MTT or INT method phases It is less than operating procedure.
The research system detected as pharmacy in vitro using A431 (EGFRwt overexpressing cells) in the present invention.In 96 orifice plates In, 6000/ hole of plating cells is carried out, after 24 hours, carries out antibody dosing.Drug level to A431 is 2nM-0.4pM.Processing MTS detects cell activity after 72 hours.
1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAE TDC、 1C7-HC-S235C-LC-V205C-mc- vc-PAB-MMAF TDC、 1C7-HC-S235C-LC-V205C-mc-vc-PAB-PBD TDC、 1C7-HC-S235C-LC- V205C-mc-vc-PAB-SN38TDC, 1C7-HC-S235C-LC-V205C-mc-vc-PAB-Dox TDC and its corresponding 1A5-mc-vc-PAB-MMAE ADC、1A5-mc-vc-PAB-MMAF ADC、 1A5-mc-vc-PAB-PBD ADC、1A5-mc- The IC50 testing results of vc-PAB-SN38ADC, 1A5-mc-vc-PAB-Dox ADC to the A431 cells of overexpression EGFR.TDC Cellular cytoxicity activity is better than ADC.
29 tumor-bearing mice Composition analyzed of embodiment
A431-EGFRwt bearing mouse models are established in the present invention, to evaluate the internal medicine of TDC and ADC coupling drugs Effect.I.e. with 3 × 106A431-EGFRwt cells are subcutaneously injected into the BALB/c nude mices both sides of 4~6 weeks age of mouse, wait for mouse Tumour mean size grows to 130~155mm3, random to be grouped, every group 5, at the 0th day, 1C7-HC-S235C-LC- V205C-mc-vc-PAB-MMAE、 1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAF、 1C7-HC-S235C-LC- V205C-mc-vc-PAB-PBD、1A5-mc-vc-PAB-MMAE、 1A5-mc-vc-PAB-MMAF、1A5-mc-vc-PAB-PBD Single intravenous injection, 1C7-HC-S235C-LC-V205C-mc-vc-PAB-SN38,1C7- are carried out with 1mg/kg dosage respectively HC-S235C-LC-V205C-mc-vc-PAB-DOX, 1A5-mc-vc-PAB-SN38,1A5-mc-vc-PAB-DOX are with 6mg/kg Dosage is administered.Tumor average volume ± SE when data are shown as measuring.
1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAE、 1C7-HC-S235C-LC-V205C-mc-vc- PAB-MMAF、 1C7-HC-S235C-LC-V205C-mc-vc-PAB-PBD、1A5-mc-vc-PAB-MMAE、 1A5-mc-vc- PAB-MMAF, 1A5-mc-vc--PAB-PBD carried out single intravenous injection with 1mg/kg dosage respectively at the 0th day.TDC groups (1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAE、 1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAF、 1C7-HC-S235C-LC-V205C-mc-vc-PAB-PBD) tumor killing effect is significantly better than ADC groups (1A5-mc-vc-PAB- MMAE、1A5-mc-vc-PAB-MMAF、1A5-mc-vc-PAB-PBD)。
1C7-HC-S235C-LC-V205C-mc-vc-PAB-SN38、 1C7-HC-S235C-LC-V205C-mc-vc- PAB-DOX, 1A5-mc-vc-PAB-SN38,1A5-mc-vc-PAB-DOX carried out single with 6mg/kg dosage respectively at the 0th day Intravenously administrable.TDC groups (1C7-HC-S235C-LC-V205C-mc-vc-PAB-SN38,1C7-HC-S235C-LC-V205C- Mc-vc-PAB-DOX) tumor killing effect is significantly better than ADC groups (1A5-mc-vc-PAB-SN38,1A5-mc-vc-PAB-DOX).
30 rat toxicity of embodiment detects
The present invention is the cysteine engineered Antibody-toxin conjugate tolerance of assessment, using normal Sprague- Dawley rats are with Single-dose intravenous injection TDC or ADC (first day), wherein 1C7-HC-S235C-LC-V205C-mc-vc- PAB-MMAE、 1C7-HC-S235C-LC-V205C-mc-vc-PAB-MMAF、 1C7-HC-S235C-LC-V205C-mc-vc- PAB-PBD, 1A5-mc-vc-PAB-MMAE, 1A5-mc-vc-PAB-MMAF, 1A5-mc-vc-PAB-PBD dosage is 50mg/kg, 1C7-HC-S235C-LC-V205C-mc-vc-PAB-SN38,1C7-HC-S235C-LC-V205C-mc-vc- PAB-DOX, 1A5-mc-vc-PAB-SN38,1A5-mc-vc-PAB-DOX dosage are 100mg/kg, monitor weight daily Situation of change.Rat is put to death after 12nd day.
TDC and ADC rat toxicities detect, changes of weight situation.At first 6 days, ADC group weight continued to decline, and 5 days gradually Restore；TDC groups and control group significant difference, show that TDC group safeties are considerably better than ADC groups.
The present invention is not limited to the range of the specific embodiment by being disclosed in embodiment, these embodiments are used for illustrating this Invention several aspects, functionally equivalent any embodiment all belong to the scope of the present invention.In fact, except illustrated herein Other than described, various modifications of the invention are also obvious to those skilled in the art and belong to this paper institutes Attached the scope of the claims.
Sequence table
<110>Baili Pharmaceutical Co., Ltd., Sichuan Prov.
<120>Cysteine engineered Antibody-toxin conjugate
<160> 12
<170> SIPOSequenceListing 1.0
<210> 1
<211> 369
<212> DNA
<213>1C7 heavy chain variable regions (VHDNA sequences)
<400> 1
caggtgcagc tgcagcagag cggcgccgag gtgaagaagc ccggcagcag cgtgaaggtg 60
agctgcaagg ccagcggcta caccttcacc aactactaca tctactgggt gcggcaggcc 120
cccggccagg gcctggagtg gatcggcggc atcaacccca ccagcggcgg cagcaacttc 180
aacgagaagt tcaagacccg ggtgaccatc accgccgacg agagcagcac caccgcctac 240
atggagctga gcagcctgcg gagcgaggac accgccttct acttctgcac ccggcagggc 300
ctgtggttcg acagcgacgg ccggggcttc gacttctggg gccagggcac caccgtgacc 360
gtgagcagc 369
<210> 2
<211> 124
<212> PRT
<213>1C7 heavy chain variable regions (VH amino acid sequences)
<400> 2
Asp Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly
1 5 10 15
Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn
20 25 30
Tyr Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
35 40 45
Ile Gly Gly Ile Asn Pro Thr Ser Gly Gly Ser Asn Phe Asn Glu Lys
50 55 60
Phe Lys Thr Arg Val Thr Ile Thr Ala Asp Glu Ser Ser Thr Thr Ala
65 70 75 80
Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Phe Tyr Phe
85 90 95
Cys Thr Arg Gln Gly Leu Trp Phe Asp Ser Asp Gly Arg Gly Phe Asp
100 105 110
Phe Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 6
<211> 339
<212> DNA
<213>1C7 light chain variable regions (VLDNA sequences)
<400> 6
gatattcaaa tgactcaatc tccttcttct ctttctgctt ctgttggtga tcgtgttact 60
attacttgtc gttcttctca aaatattgtt cattctaatg gtaatactta tcttgattgg 120
tatcaacaaa ctcctggtaa agctcctaaa cttcttattt ataaagtttc taatcgtttt 180
tctggtgttc cttctcgttt ttctggttct ggttctggta ctgattttac ttttactatt 240
tcttctcttc aacctgaaga tattgctact tattattgtt ttcaatattc tcatgttcct 300
tggacttttg gtcaaggtac taaacttcaa attactcgt 339
<210> 7
<211> 113
<212> PRT
<213>1C7 light chain variable regions (VL amino acid sequences)
<400> 7
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Asn Ile Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Gln Gln Thr Pro Gly Lys Ala
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
65 70 75 80
Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Phe Gln Tyr
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr
100 105 110
Arg
<210> 11
<211> 1359
<212> DNA
<213>1C7 heavy chains (HCDNA sequences)
<400> 11
caggtgcagc tgcagcagag cggcgccgag gtgaagaagc ccggcagcag cgtgaaggtg 60
agctgcaagg ccagcggcta caccttcacc aactactaca tctactgggt gcggcaggcc 120
cccggccagg gcctggagtg gatcggcggc atcaacccca ccagcggcgg cagcaacttc 180
aacgagaagt tcaagacccg ggtgaccatc accgccgacg agagcagcac caccgcctac 240
atggagctga gcagcctgcg gagcgaggac accgccttct acttctgcac ccggcagggc 300
ctgtggttcg acagcgacgg ccggggcttc gacttctggg gccagggcac caccgtgacc 360
gtgagcagcg ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc 420
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg 480
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta 540
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc 600
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga 660
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc 720
ctggggggac cgtgcgtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc 780
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag 840
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag 900
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg 960
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa 1020
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc 1080
cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc 1140
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg 1200
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag 1260
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac 1320
cactacacgc agaagagcct ctccctgtct ccgggttaa 1359
<210> 12
<211> 452
<212> PRT
<213>1C7 heavy chains (HC amino acid sequences)
<400> 12
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Gly Ile Asn Pro Thr Ser Gly Gly Ser Asn Phe Asn Glu Lys Phe
50 55 60
Lys Thr Arg Val Thr Ile Thr Ala Asp Glu Ser Ser Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Phe Tyr Phe Cys
85 90 95
Thr Arg Gln Gly Leu Trp Phe Asp Ser Asp Gly Arg Gly Phe Asp Phe
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Cys Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
450
<210> 13
<211> 660
<212> DNA
<213>1C7 light chains (LCDNA sequences)
<400> 13
gatattcaaa tgactcaatc tccttcttct ctttctgctt ctgttggtga tcgtgttact 60
attacttgtc gttcttctca aaatattgtt cattctaatg gtaatactta tcttgattgg 120
tatcaacaaa ctcctggtaa agctcctaaa cttcttattt ataaagtttc taatcgtttt 180
tctggtgttc cttctcgttt ttctggttct ggttctggta ctgattttac ttttactatt 240
tcttctcttc aacctgaaga tattgctact tattattgtt ttcaatattc tcatgttcct 300
tggacttttg gtcaaggtac taaacttcaa attactcgta cggtggctgc accatctgtc 360
ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgcctctgt tgtgtgcctg 420
ctgaataact tctatcccag agaggccaaa gtacagtgga aggtggataa cgccctccaa 480
tcgggtaact cccaggagag tgtcacagag caggacagca aggacagcac ctacagcctc 540
agcagcaccc tgacgctgag caaagcagac tacgagaaac acaaagtcta cgcctgcgaa 600
gtcacccatc agggcctgag ctcgccctgc acaaagagct tcaacagggg agagtgttag 660
<210> 14
<211> 219
<212> PRT
<213>1C7 light chains (LC amino acid sequences)
<400> 14
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Asn Ile Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Gln Gln Thr Pro Gly Lys Ala
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
65 70 75 80
Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Phe Gln Tyr
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Cys Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 15
<211> 1359
<212> DNA
<213>1A5 heavy chains (HCDNA sequences)
<400> 15
caggtgcagc tgcagcagag cggcgccgag gtgaagaagc ccggcagcag cgtgaaggtg 60
agctgcaagg ccagcggcta caccttcacc aactactaca tctactgggt gcggcaggcc 120
cccggccagg gcctggagtg gatcggcggc atcaacccca ccagcggcgg cagcaacttc 180
aacgagaagt tcaagacccg ggtgaccatc accgccgacg agagcagcac caccgcctac 240
atggagctga gcagcctgcg gagcgaggac accgccttct acttctgcac ccggcagggc 300
ctgtggttcg acagcgacgg ccggggcttc gacttctggg gccagggcac caccgtgacc 360
gtgagcagcg ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc 420
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg 480
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta 540
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc 600
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga 660
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc 720
ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc 780
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag 840
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag 900
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg 960
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa 1020
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc 1080
cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc 1140
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg 1200
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag 1260
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac 1320
cactacacgc agaagagcct ctccctgtct ccgggttaa 1359
<210> 16
<211> 452
<212> PRT
<213>1A5 heavy chains (HC amino acid sequences)
<400> 16
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Gly Ile Asn Pro Thr Ser Gly Gly Ser Asn Phe Asn Glu Lys Phe
50 55 60
Lys Thr Arg Val Thr Ile Thr Ala Asp Glu Ser Ser Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Phe Tyr Phe Cys
85 90 95
Thr Arg Gln Gly Leu Trp Phe Asp Ser Asp Gly Arg Gly Phe Asp Phe
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
450
<210> 17
<211> 660
<212> DNA
<213>1A5 light chains (LCDNA sequences)
<400> 17
gatattcaaa tgactcaatc tccttcttct ctttctgctt ctgttggtga tcgtgttact 60
attacttgtc gttcttctca aaatattgtt cattctaatg gtaatactta tcttgattgg 120
tatcaacaaa ctcctggtaa agctcctaaa cttcttattt ataaagtttc taatcgtttt 180
tctggtgttc cttctcgttt ttctggttct ggttctggta ctgattttac ttttactatt 240
tcttctcttc aacctgaaga tattgctact tattattgtt ttcaatattc tcatgttcct 300
tggacttttg gtcaaggtac taaacttcaa attactcgta cggtggctgc accatctgtc 360
ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgcctctgt tgtgtgcctg 420
ctgaataact tctatcccag agaggccaaa gtacagtgga aggtggataa cgccctccaa 480
tcgggtaact cccaggagag tgtcacagag caggacagca aggacagcac ctacagcctc 540
agcagcaccc tgacgctgag caaagcagac tacgagaaac acaaagtcta cgcctgcgaa 600
gtcacccatc agggcctgag ctcgcccgtc acaaagagct tcaacagggg agagtgttag 660
<210> 18
<211> 219
<212> PRT
<213>1A5 light chains (LC amino acid sequences)
<400> 18
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Asn Ile Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Gln Gln Thr Pro Gly Lys Ala
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
65 70 75 80
Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Phe Gln Tyr
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

Claims (12)

1. cysteine engineered Antibody-toxin conjugate (TDC) has general formula：
1C7-HC-S235C-LC-V205C-mc-vc-PAB-payload。
2. cysteine engineered Antibody-toxin conjugate described in claim 1, wherein 1C7 is target antibody heavy chain 235 205 valines (V) of serine (S) and light chain transform the antibody after cysteine (C) as；1C7 heavy chain amino acid sequences are SEQ ID NO:12, light-chain amino acid sequence is SEQ ID NO:14.
3. the cysteine engineered Antibody-toxin conjugate described in claim 2, including a ripe heavy chain, amino Acid sequence at least 90% and SEQ ID NO:12 is identical.
4. the cysteine engineered Antibody-toxin conjugate described in claim 2, including a ripe light chain, amino Acid sequence at least 90% and SEQ ID NO:14 is identical.
5. cysteine engineered Antibody-toxin conjugate described in claim 1, wherein mc-vc-PAB-OH connexons are：
6. cysteine engineered Antibody-toxin conjugate described in claim 1, wherein Payload is small molecule high activity Cytotoxin, including but not limited to MMAE, MMAF, PBD, SN-38 and Dox；MMAE, MMAF, PBD, SN-38 and Dox molecular formula For：
7. cysteine engineered Antibody-toxin conjugate described in claim 1, wherein toxin are than antibody ratios (DAR) 3.2-4.0。
8. the cysteine engineered Antibody-toxin conjugate described in claim 2, mc-vc-PAB connexons are carried out with antibody The site amino sequence of site-directed coupling is：PELLGGPCVFLFPP and GLSSPCTKSFN, whereinCRespectively target antibody weight The cysteine of 235 serines of chain and the transformation of 205 valines of light chain.
9. the cysteine engineered Antibody-toxin conjugate described in claim 2,1C7 antibody be selected from IgG1, IgG2, IgG3, IgG4。
10. the cysteine engineered Antibody-toxin conjugate described in claim 2,1C7 antibody light chains conserved region are selected from Kappa and lamda sequences.
11. cysteine engineered Antibody-toxin conjugate described in claim 1, indication is to be overexpressed EGFRwt Tumour, including it is head and neck cancer, colorectal cancer, brain colloid carcinoma, cancer of pancreas, non-small cell lung cancer, carcinoma of urinary bladder, colorectal cancer, kidney, preceding Row gland cancer, breast cancer etc..
12. cysteine engineered Antibody-toxin conjugate described in claim 1, main site-directed coupling step are：First Using DTT also original antibodies, the shielding on the cysteine residues being transformed on antibody is released, and remove by cation-exchange chromatography DTT and screen；Then DHAA oxidised antibodies are used, the interchain disulfide bond of antibody is made to reconnect；It is eventually adding mc-vc- PAB-payload and the cysteine residues of antibody transformation are coupled, and are not coupled upper antibody by cation-exchange chromatography removal The mc-vc-PAB-payload of molecule.
CN201810371080.XA 2018-04-24 2018-04-24 Cysteine engineered antibody-toxin conjugates Active CN108714220B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810371080.XA CN108714220B (en) 2018-04-24 2018-04-24 Cysteine engineered antibody-toxin conjugates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810371080.XA CN108714220B (en) 2018-04-24 2018-04-24 Cysteine engineered antibody-toxin conjugates

Publications (2)

Publication Number Publication Date
CN108714220A true CN108714220A (en) 2018-10-30
CN108714220B CN108714220B (en) 2021-11-19

Family

ID=63899038

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810371080.XA Active CN108714220B (en) 2018-04-24 2018-04-24 Cysteine engineered antibody-toxin conjugates

Country Status (1)

Country Link
CN (1) CN108714220B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023024949A1 (en) * 2021-08-24 2023-03-02 昆山新蕴达生物科技有限公司 Antibody-drug conjugate conjugated via breakable linker

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687037A (en) * 2007-05-08 2010-03-31 健泰科生物技术公司 Cysteine engineered anti-MUC 16 antibodies and antibody drug conjugates
US20150071923A1 (en) * 2013-09-12 2015-03-12 Ge Wei Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
CN106467575A (en) * 2015-08-18 2017-03-01 四川百利药业有限责任公司 Cysteine engineered Antibody-toxin conjugate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687037A (en) * 2007-05-08 2010-03-31 健泰科生物技术公司 Cysteine engineered anti-MUC 16 antibodies and antibody drug conjugates
US20150071923A1 (en) * 2013-09-12 2015-03-12 Ge Wei Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
CN106467575A (en) * 2015-08-18 2017-03-01 四川百利药业有限责任公司 Cysteine engineered Antibody-toxin conjugate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023024949A1 (en) * 2021-08-24 2023-03-02 昆山新蕴达生物科技有限公司 Antibody-drug conjugate conjugated via breakable linker

Also Published As

Publication number Publication date
CN108714220B (en) 2021-11-19

Similar Documents

Publication Publication Date Title
CN111434692B (en) anti-CLD18A2 nano antibody and application thereof
US11248030B2 (en) Dual IL-2R and IL-7R binding compounds
KR20180030899A (en) PD-L1 (&amp;quot; Programmed Killing-Ligand 1 &amp;quot;) antibody
TWI812918B (en) IL-7Rαγc BINDING COMPOUNDS
KR20150063447A (en) Antibodies recognizing alpha-synuclein
CN109081871A (en) Antibody-drug conjugates
CN105073197A (en) Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
AU2016290523B2 (en) Fusion proteins which bind to human Fc receptors
PT1694706E (en) Modified anti-cd52 antibody
CN108727498B (en) Cysteine engineered antibody-toxin conjugates
EP4331616A1 (en) Antibody drug conjugate, preparation method therefor and application thereof
CN108714220B (en) Cysteine engineered antibody-toxin conjugates
CN110760005A (en) Chimeric antigen receptor modified T cell of targeted Glypican-3 antigen and application thereof
CN110382540A (en) VEGFR-2 antibody
US20230279106A1 (en) Antigen Binding Proteins
CN115279406A (en) Formulations of protein therapeutics
RU2815823C2 (en) Isolated bispecific antibody that specifically binds to cd47 and pd-l1
AU778551B2 (en) Novel peptide and screening method by using the same
CN114437219B (en) anti-LAG-3 nano antibody, encoding gene, recombinant nano antibody, recombinant vector, recombinant strain and application
AU2022386505A1 (en) Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
WO2022173036A1 (en) Human denatured crp specific neutralizing antibody, and medicine and anti-inflammatory agent containing said antibody
CN117858904A (en) Isolated bispecific antibodies that specifically bind CD47 and PD-L1
Bzymek et al. Meditope–Fab interaction: threading the hole
TW201208701A (en) Anti-EPHA2 antibodies and uses thereof
CN115703838A (en) Bispecific binding molecules that specifically bind VEGF and PPK and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210520

Address after: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province

Applicant after: Sichuan Baili Pharm Co.,Ltd.

Applicant after: Chengdu duote antibody medicine Co.,Ltd.

Address before: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province

Applicant before: Sichuan Baili Pharm Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province

Patentee after: SICHUAN BAILI PHARM Co.,Ltd.

Patentee after: Chengdu bailidote Biological Pharmaceutical Co., Ltd

Address before: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province

Patentee before: SICHUAN BAILI PHARM Co.,Ltd.

Patentee before: Chengdu duote antibody drug Co., Ltd

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220105

Address after: 610000 Building 1, No. 161 Baili Road, Chengdu cross strait science and Technology Industrial Development Park, Wenjiang District, Chengdu, Sichuan

Patentee after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Address before: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province

Patentee before: SICHUAN BAILI PHARM Co.,Ltd.

Patentee before: Chengdu bailidote Biological Pharmaceutical Co., Ltd